The FDA has approved Hovilpri for immunocompromised adults with refractory mucocutaneous HSV lesions, offering a novel oral treatment.

Two respiratory syncytial virus (RSV) vaccines, RSVPreF3+AS01 and RSVpreF, were highly effective at preventing hospital admissions and death among older adults during the 2023 to 2024 season. These ...

The M72/AS01 TB vaccine was safe for virologically suppressed adults with HIV, with no severe vaccine-related AEs reported.

Adults hospitalized with CAP face high mortality rates, particularly those with unsuppressed HIV and tuberculosis.

Coadministration of the MenACYW-TT vaccine with routine pediatric immunizations is well tolerated among healthy infants and ...

Topline phase 3 OPUS-1 data show VAX-31 met coprimary immunogenicity endpoints, demonstrating noninferiority and superiority for key pneumococcal serotypes.

People with HIV experience a significantly greater increase in multimorbidity following COVID-19 diagnosis compared with those without HIV.

An MF59-adjuvanted, higher-dose influenza vaccine improves immune responses in older adults compared with standard egg-based options.

Meningitis incidence and mortality declined significantly in the Western Pacific Region from 1990 to 2023 following expanded vaccination initiatives.

Among neurocritical patients, older age and COPD are significant risk factors for VAP, according to a systematic review and meta-analysis.

Adults with HIV aged 60 years and older are more likely to report favorable quality of life (QOL) following a switch in antiretroviral therapy (ART) than adults younger than 60 ye ...

The respiratory syncytial virus prefusion F protein-based vaccine does not increase the risk for severe myocarditis or pericarditis in adults.